期刊文献+

阿托伐他汀对陈旧性心肌梗死病人心功能及运动耐量的影响 被引量:2

Effects of Atorvastatin on Cardiac Function and Exercise Tolerance in Patients with Old Myocardial Infarction
下载PDF
导出
摘要 目的观察阿托伐他汀对血脂正常的陈旧性心肌梗死病人心功能及运动耐量的影响。方法选择57例陈旧性心肌梗死病人,随机分为两组,对照组给予硝酸异山梨酯(消心痛)10mg,口服,每日3次,连用8周,观察组给予阿托伐他汀10mg,口服,每日服1次,连用8周;比较两组每周心绞痛发作次数、硝酸甘油耗减量、心功能及运动耐量。结果阿托伐他汀可减少心绞痛发作次数、硝酸甘油耗减量,增加运动至出现ST段压低1mm所需时间、心绞痛所需时间,ST段缺血型下移之和明显减少;左室射血分数、心输出量、左室短轴缩短分数均增加,左室舒张末期内径无明显变化。结论阿托伐他汀改善运动诱发的心肌缺血,并提高心功能及运动耐量。 Objective To evaluate the effect of atorvastatin on cardiac function and exercise tolerance in patients with old myocardial infarction.Methods Fifty seven patients with old myocardial infarction were give nisosorbide dinitrate or atorvastatin for 8 weeks randomly.Exercise tolerance was evaluated by treadmill exercise testing, cardiac function by Doppler ultrasound respectively before and after therapy.Results After atorvastatin treating, frequency of angina pectoris attack and consumption of nitroglycerin weekly decreased significantly;the time for inducing angina and the time to 0.1mV ST segment depression,or ∑ST depression by exercise improved significantly(P<0.01).Left ventricular ejecting fraction,fractional shortening,cardiac output increased(P<0.01),and the left ventricular end-diastole diameter did not decreased (P>0.05).Conclusion Atorvastatin can improve myocardial ischemia,cardiac function and exercise tolerance induced by exercise.
出处 《中西医结合心脑血管病杂志》 2005年第7期589-590,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 阿托伐他汀 心肌梗死 心功能 心肌缺血 运动耐量 atorvastatin myocardial infarction cardiac function myocardial ischemia exercise tolerance
  • 相关文献

参考文献8

  • 1李晓飞,杨奕清,刘懿,徐文渊,陈义汉.辛伐他汀对血脂正常的稳定型心绞痛患者的抗心肌缺血作用[J].临床心血管病杂志,2002,18(8):378-380. 被引量:20
  • 2王景全,高丽红,刘闺男,齐国先,周妍.氟伐他汀对高胆固醇血症患者血清NO及血管内皮功能的影响[J].中国药理学通报,2004,20(11):1284-1286. 被引量:6
  • 3Crisby M,Nordin-Fredriksson G,Shah PK,et al.Pravastatin treament increases collagen content and decreases lipid content,inflammation,metalloproteinases,and cell death in human carotid plaques:implications for plaque stabilization[J].Circulation,2001,103(7):926-933.
  • 4Corti R,Fayad ZA,Fuster V,et al.Effects of lipid- lowering by simvastatin on human atherosclerotic lesions:a longitudinal study by highresolution,noninvasive magnetic resonance imaging[J].Circulation,2001,104(3):249-252.
  • 5Heart Protection Study Collaborative Group.MRC/ BHF Heart Protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial[J].Lancet,2002,360(9326):7-22.
  • 6Cotton JM,Kearney MT,Shah AM.Nitric oxide and myocardial function in heart failure:friend or foe[J].Heart,2002,88:564-566.
  • 7Liao JK.Statin therapy for cardiac hypertrophy and heart failure[J].J Investig Med,2004,52(4):248-253.
  • 8肖立中,林晓云,马绍椿,黄志,唐良秋,徐新,赖少燕.阿托伐他汀对扩张型心肌病患者心功能及心率变异性的影响[J].临床心血管病杂志,2004,20(3):133-135. 被引量:5

二级参考文献32

  • 1[1]Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation, 2003, 108:839-843.
  • 2[2]Pliquett R U, Cornish K G, Zucker I H, et al.Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol, 2003, 95: 700-704.
  • 3[3]Shishehbor M H, Brennan M L, Aviles R J, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation, 2003, 108: 426-431.
  • 4[4]Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and represents a target for statin treatment. Circulation, 2003, 108:1567-1574.
  • 5[5]Krum H, Mcmurray J J. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol, 2002, 39:1567-1573.
  • 6[6]von Haehling S, Anker S D, Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev, 2003, 8: 99-106.
  • 7[7]Cotton J M, Kearney M T,Shah A M. Nitric oxide and myocardial function in heart failure: friend or foe? Heart, 2002, 88:564-566.
  • 8[8]Schwartzkopff B, Fassbach M, Pelzer B, et al. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail, 2002, 4:439-444.
  • 9[9]Luan Z, Chase A J, Newby A C. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol, 2003, 23:769-775.
  • 10[10]King M K, Coker M L, Goldberg A,et al. Selective matrix metalloproteinase inhibition with developing heart failure: Effects on left ventricular function and structure. Circ Res, 2003, 92:177-185.

共引文献26

同被引文献6

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部